Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Bladder Cancer in 18 Major Markets
Bladder Cancer is cancer arising in the urinary bladder, generally from urothelial cells. It is the fourth most common cancer in males and the ninth most common in females. While Bladder Cancer is associated with significant morbidity and mortality, prognosis tends to be good with 80-100% survival at 5 years. However, Bladder Cancer can also have high recurrence rates; therefore patients that have had bladder cancer require life-long monitoring.
This report provides the current incident population for Bladder Cancer across 18 Major Markets (USA, France, Germany, Italy, Spain, UK, Hungary, Turkey, Russia, Japan, India, Australia, Canada, Argentina, Brazil, Mexico, South Africa and Saudi Arabia) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Bladder Cancer have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for Bladder Cancer include:
• Smoking
• Occupation
• Bladder infections
• Bladder stones
• Family history of bladder cancer
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global Bladder Cancer’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the incidence of the subdivided types of Bladder Cancer and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Bladder Cancer incident population.
• Identify sub-populations within Bladder Cancer which require treatment.
• Gain an understanding of the specific markets that have the largest number of Bladder Cancer patients.
Table of Contents
• List of Tables and Figures
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key Co-morbid Conditions associated with the Disease
• Methodology for Quantification of Patient Numbers
• Top-Line Bladder Cancer Incidence
• Stages and Histopathology of Bladder Cancer
o Jewett Strong Marshall Staging of Bladder Cancer
o Anatomical Location of Bladder Cancer
o Major Histopathology in Bladder Cancer
o Smoking Status in Bladder Cancer
• Abbreviations and Acronyms used in the Report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
List of Figures
• Percentage total incident cases by age group
List of Tables
• Comparison of AJCC and Jewett-Strong-Marshall Staging Systems for Bladder Cancer
• Incidence of Bladder Cancer, total (000s)
• Incidence of Bladder Cancer, males (000s)
• Incidence of Bladder Cancer, females (000s)
• JSM staging in Bladder Cancer patients, total (000s)
• Anatomical Location of Bladder Cancer, total (000s)
• Major histopathology type of Bladder Cancer, total (000s)
• Smoking Status in Bladder Cancer, total (000s)
• Abbreviations and Acronyms used in the report
• USA Incidence of Bladder Cancer by 5-yr age cohort, males (000s)
• USA Incidence of Bladder Cancer by 5-yr age cohort, females (000s)
• France Incidence of Bladder Cancer by 5-yr age cohort, males (000s)
• France Incidence of Bladder Cancer by 5-yr age cohort, females (000s)
• Germany Incidence of Bladder Cancer by 5-yr age cohort, males (000s)
• Germany Incidence of Bladder Cancer by 5-yr age cohort, females (000s)
• Italy Incidence of Bladder Cancer by 5-yr age cohort, males (000s)
• Italy Incidence of Bladder Cancer by 5-yr age cohort, females (000s)
• Spain Incidence of Bladder Cancer by 5-yr age cohort, males (000s)
• Spain Incidence of Bladder Cancer by 5-yr age cohort, females (000s)
• United Kingdom Incidence of Bladder Cancer by 5-yr age cohort, males (000s)
• United Kingdom Incidence of Bladder Cancer by 5-yr age cohort, females (000s)
• Hungary Incidence of Bladder Cancer by 5-yr age cohort, males (000s)
• Hungary Incidence of Bladder Cancer by 5-yr age cohort, females (000s)
• Turkey Incidence of Bladder Cancer by 5-yr age cohort, males (000s)
• Turkey Incidence of Bladder Cancer by 5-yr age cohort, females (000s)
• Russia Incidence of Bladder Cancer by 5-yr age cohort, males (000s)
• Russia Incidence of Bladder Cancer by 5-yr age cohort, females (000s)
• Japan Incidence of Bladder Cancer by 5-yr age cohort, males (000s)
• Japan Incidence of Bladder Cancer by 5-yr age cohort, females (000s)
• India Incidence of Bladder Cancer by 5-yr age cohort, males (000s)
• India Incidence of Bladder Cancer by 5-yr age cohort, females (000s)
• Australia Incidence of Bladder Cancer by 5-yr age cohort, males (000s)
• Australia Incidence of Bladder Cancer by 5-yr age cohort, females (000s)
• Canada Incidence of Bladder Cancer by 5-yr age cohort, males (000s)
• Canada Incidence of Bladder Cancer by 5-yr age cohort, females (000s)
• Argentina Incidence of Bladder Cancer by 5-yr age cohort, males (000s)
• Argentina Incidence of Bladder Cancer by 5-yr age cohort, females (000s)
• Brazil Incidence of Bladder Cancer by 5-yr age cohort, males (000s)
• Brazil Incidence of Bladder Cancer by 5-yr age cohort, females (000s)
• Mexico Incidence of Bladder Cancer by 5-yr age cohort, males (000s)
• Mexico Incidence of Bladder Cancer by 5-yr age cohort, females (000s)
• South Africa Incidence of Bladder Cancer by 5-yr age cohort, males (000s)
• South Africa Incidence of Bladder Cancer by 5-yr age cohort, females (000s)
• Saudi Arabia Incidence of Bladder Cancer by 5-yr age cohort, males (000s)
• Saudi Arabia Incidence of Bladder Cancer by 5-yr age cohort, females (000s)
